AR and neoplasm: The impact of DDR gene alterations and other biomarkers on the clinical outcome of radiometabolic agents in mCRPC is under investigation [28,29], but there are no data about the association between DDR gene alterations and other clinical-biological features rising during the clinical history of mCRPC as PSA/tumor flare, neuroendocrine differentiation, androgen receptor amplification and others [30,31,32,33].